학술논문
Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease.
Document Type
Article
Author
Source
Subject
*BIOMARKERS
*CARDIOVASCULAR diseases risk factors
*CONFIDENCE intervals
*STATISTICAL correlation
*DNA
*ENZYME-linked immunosorbent assay
*FIBRINOLYSIS
*GENETIC polymorphisms
*HYPERTENSION
*TYPE 2 diabetes
*POLYMERASE chain reaction
*PROBABILITY theory
*RESEARCH funding
*STATISTICS
*T-test (Statistics)
*THROMBOSIS
*TRIGLYCERIDES
*DATA analysis
*MULTIPLE regression analysis
*METABOLIC syndrome
*CROSS-sectional method
*DATA analysis software
*GENOTYPES
*ONE-way analysis of variance
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2314-6133
Abstract
Background. Metabolic and genetic factors induce plasminogen activator inhibitor type-1 (PAI-1) overexpression; higher PAI-1 levels decrease fibrinolysis and promote atherothrombosis. Aim. To assess PAI-1 antigen levels among subjects with type 2 diabetes mellitus (T2DM) plus Metabolic Syndrome (MetS) before clinical manifestations of atherothrombosis and the contribution of metabolic factors and 4G/5G polymorphism of PAI-1 gene on the variability of PAI-1. Methods. We conducted an observational, cross-sectional assay in a hospital in Mexico City from May 2010 to September 2011. MetS was defined by the International Diabetes Federation criteria. PAI-1 levels and 4G/5G polymorphism were determined by ELISA and PCR-RFLP analysis. Results. We enrolled 215 subjects with T2DM plus MetS and 307 controls. Subjects with T2DM plus MetS had higher PAI-1 levels than the reference group (58.4 ± 21 versus 49.9 ± 16 ng/mL, p=0.026). A model with components of MetS explained only 12% of variability on PAI-1 levels (R2 = 0.12; p=0.001), with β=0.18 (p=0.03) for hypertension, β=-0.16 (p=0.05) for NL HDL-c, and β=0.15 (p=0.05) for NL triglycerides. Conclusion. Subjects with T2DM plus MetS have elevated PAI-1 levels before clinical manifestations of atherothrombotic disease. Metabolic factors have a more important contribution than 4G/5G polymorphism on PAI-1 plasma variability. [ABSTRACT FROM AUTHOR]